Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • Women of reproductive age who have been diagnosed with HCV infection should be counseled about the benefit of antiviral treatment before pregnancy
  • Treatment with DAAs during pregnancy is not recommended as only limited safety and efficacy data are available (Management Guidelines)[AASLD-IDSA HCV; Chappell 2020]
  • Ribavirin is contraindicated in pregnancy due to its known teratogenic effects

    Action required

    Keywords: Hepatitis C, Hepatitis C-Diagnosis, Hepatitis C-Special Populations, Hepatitis C-Sustained Virologic Response, Hepatitis C-Treatment

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.